You are here

INDUCTION OF ANTI-HPV CTL WITH PEPTIDE-CPG DNA CONJUGATE

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AI052707-01
Agency Tracking Number: AI052707
Amount: $119,349.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2002
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
DYNAVAX TECHNOLOGIES CORPORATION 717 POTTER ST, STE 100
BERKELEY, CA 94710
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 JILL WILKEN
 (510) 848-5100
 JWILKEN@DVAX.COM
Business Contact
 DINA DINO
Phone: (510) 848-5100
Email: DDINA@DVAX.COM
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant): The goal of this research program is to produce peptide-immunostimulatory (ISS) DNA conjugates that can stimulate robust anti-papillomavirus Th1 and CTL responses. Successful peptide-ISS conjugates could be used alone or in combination with other papilloma antigens to produce a vaccine for the prevention or treatment of human papillomavirus infection. In the Phase I program, chemical conjugates will be made of peptides encompassing helper T cell and cytotoxic T cell (CTL) epitopes of the HPV oncoprotein E7 and immunostimulatory DNA sequences (ISS) known to stimulate strong Th1 and CTL responses. The ability of these peptide-ISS conjugates to induce Th1 and cytotoxic T cell responses will be tested in mice. The E7 peptide-ISS conjugates will also be co-injected with the HPV capsid protein L1 to determine the ability of E7-peptide conjugates to influence the quality and magnitude antibody and T cell responses to the capsid protein. If Phase I results prove this approach is feasible, Phase II studies will involve preparation of peptide-ISS conjugates encompassing significant portions of HPV E7 and/or E6, testing those conjugates for induction of immune responses when injected singly and together with other HPV antigens, and preparation of peptide-ISS conjugate formulations that could be used in human clinical trials.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government